First Rate Infusion and Wellness- First Rate Ketamine Clinic
2540 North Galloway Avenue, Suite 303 Building 3, Mesquite
4.9(114 Google reviews)
United States
1 listed treatment center serving Mesquite and the surrounding area.
2540 North Galloway Avenue, Suite 303 Building 3, Mesquite
4.9(114 Google reviews)
Every dose is given in a certified healthcare setting, followed by at least two hours of monitoring. Arrange transportation home after each visit. Distances below are straight-line miles from Mesquite.
10.4 miles away · Dallas
411 North Washington Avenue, Suite 5200, Dallas
4.8(107 Google reviews)
11.2 miles away · Rockwall
1010 West Ralph Hall Parkway, Ste 112, Rockwall
4.8(45 Google reviews)
11.4 miles away · Dallas
5307 East Mockingbird Lane, 915, Dallas
4.0(12 Google reviews)
12.6 miles away · Rockwall
810 East Ralph Hall Parkway, 140, Rockwall
4.4(64 Google reviews)
13.8 miles away · Dallas
14.3 miles away · Dallas
12221 Merit Drive, 450, Dallas
4.7(90 Google reviews)
The cost of SPRAVATO® treatment depends on your insurance benefits, the treatment setting, and how services are billed. Both the medication and the visit for supervised dosing and monitoring may generate charges. Ask for an estimate that includes all parts of treatment, rather than the medication alone.
Insurers commonly require prior authorization before treatment begins. Your prescriber may need to submit records of earlier antidepressant trials, including which medicines you took and how you responded. Ask whether the center helps gather records and submit authorization requests. Approval does not necessarily mean you will have no out-of-pocket costs.
Medicare coverage may fall under Part B or Part D depending on the plan and setting. Texas Medicaid coverage also depends on the applicable program and plan requirements. The Mesquite listing currently indicates that the center does not accept Medicare or Medicaid; confirm directly before scheduling. That listing does not establish whether those programs might cover treatment elsewhere.
Manufacturer savings programs exist for eligible commercially insured patients, but not for people using government insurance. Eligibility rules apply, and assistance may not cover every charge. Ask for current program terms rather than assuming you qualify.
Before starting, ask the center and your insurer:
Keep notes about benefit discussions, and clarify any differences between the center’s estimate and your insurer’s explanation.
SPRAVATO® treatment takes place only in a REMS-certified healthcare setting. You administer the nasal spray yourself under direct observation, and it never goes home with you. Mesquite has one listed center offering Spravato, but its REMS certification is not confirmed in this directory’s information. Verify certification and appointment availability directly before making plans.
The typical labeled schedule starts with twice-weekly treatment during weeks 1–4, followed by weekly visits during weeks 5–8. Maintenance visits may then be weekly or every two weeks. Your prescriber determines the schedule appropriate for you; do not assume your appointments will follow a fixed pattern indefinitely.
Allow substantial time for each appointment: monitoring lasts at least two hours after each dose, with additional time potentially needed for check-in, preparation, and discharge assessment. Ask the center how much time to reserve before arranging work shifts, childcare, or other responsibilities.
You need someone else to drive you home. You must not drive or operate machinery until the next day after a restful sleep. Arrange a reliable ride for every visit, and ask the center about its pickup requirements before relying on a taxi or rideshare. A backup driver can help if your usual ride becomes unavailable.
If no Mesquite center is listed when you search, or the local option cannot accommodate you, the directory also lists centers in Dallas, Fort Worth, and McKinney. Confirm certification, insurance acceptance, and scheduling with each center. Compare the practical burden of repeated trips rather than choosing solely by appointment availability.
This directory lists one Mesquite center offering SPRAVATO®, but its REMS certification is not confirmed in the available listing. Ask the center to confirm that it is currently REMS-certified before scheduling treatment. If it cannot meet your needs, you can also explore listings in Dallas, Fort Worth, or McKinney. A directory listing alone does not verify certification, appointment availability, or insurance acceptance.
Spravato is FDA-approved for adults with treatment-resistant depression, either alone or with an oral antidepressant. It is also approved with an oral antidepressant for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. It is not approved for children. A clinician must review your symptoms, treatment history, and medical risks to decide whether it is appropriate; meeting an approved indication does not guarantee eligibility.
Coverage depends on your plan, the treatment setting, and authorization requirements. Insurers commonly request documentation of previous antidepressant trials. Ask about coverage for both the medication and the supervised treatment visit. The Mesquite listing indicates that the center does not accept Medicare or Medicaid, so confirm directly. That does not mean these programs never cover Spravato at other settings.
You self-administer the nasal spray under a healthcare provider’s direct observation at a REMS-certified setting. After each dose, staff monitor you for at least two hours for effects such as sedation, dissociation, breathing problems, and blood pressure increases. Allow additional time for preparation and discharge assessment. Arrange someone else to drive you home; you cannot drive until the next day after a restful sleep.
Important risks include sedation, dissociation, respiratory depression, and increased blood pressure. Dissociation can feel like being disconnected from yourself or your surroundings. Spravato also has boxed warnings concerning abuse and misuse and suicidal thoughts and behaviors, and it is a Schedule III controlled substance. Discuss your medical history, medicines, and substance use history openly with your clinician, and tell staff about concerning symptoms during monitoring.
No. Spravato has not been demonstrated to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when clinically needed. Although it has an approved use for depressive symptoms in certain adults experiencing an acute suicidal crisis, that is not a reason to delay urgent help. If you are in crisis, call or text 988. For immediate danger or a medical emergency, call 911.
Approved uses, nearby treatment centers, and medically sourced patient guides.